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 Summary
 Background: to assess inter-observer agreement of whole-body computed tomography (WBCT) in staging and 
response assessment in lymphoma according to the Lugano classification.
 Material/Methods: Retrospective analysis was conducted of 115 consecutive patients with lymphomas (45 females, 
70 males; mean age of 46 years). Patients underwent WBCT with a 64 multi-detector CT device 
for staging and response assessment after a complete course of chemotherapy. Image analysis 
was performed by 2 reviewers according to the Lugano classification for staging and response 
assessment.
 Results: The overall inter-observer agreement of WBCT in staging of lymphoma was excellent (k=0.90, 
percent agreement=94.9%). There was an excellent inter-observer agreement for stage I (k=0.93, 
percent agreement=96.4%), stage II (k=0.90, percent agreement=94.8%), stage III (k=0.89, percent 
agreement=94.6%) and stage IV (k=0.88, percent agreement=94%). The overall inter-observer 
agreement in response assessment after a completer course of treatment was excellent (k=0.91, 
percent agreement=95.8%). There was an excellent inter-observer agreement in progressive 
disease (k=0.94, percent agreement=97.1%), stable disease (k=0.90, percent agreement=95%), 
partial response (k=0.96, percent agreement=98.1%) and complete response (k=0.87, Percent 
agreement=93.3%).
 Conclusions: We concluded that WBCT is a reliable and reproducible imaging modality for staging and treatment 
assessment in lymphoma according to the Lugano classification.
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Lymphomas, both Hodgkin lymphomas and non-Hodgkin 
lymphomas, comprise approximately 5% to 6% of all malig-
nancies, approximately half of all newly diagnosed hemato-
logical tumors and are the fifth most frequently occurring 
type of cancer in the United States [1,2]. Optimal lymphoma 
management requires accurate pretreatment staging and 
reliable assessment of response during and after therapy 
[2,3]. Staging is used to define the anatomic distribution 
of the disease for purposes of prognosis and treatment 
planning. Response to treatment serves as an important 
surrogate for other measures of clinical benefit such as 
progression-free survival and overall survival. Response is 
also an important guide in decisions regarding continuation 
or change of therapy [2–6]. Different classification systems 
are applied for staging and follow-up of lymphomas. The 
Lugano classification is the most recent classification sys-
tem used for staging and treatment response assessment in 
lymphomas [4–6].
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Cross-sectional structural and functional imaging plays 
a crucial role in staging and response assessment in lym-
phomas. Whole-body imaging plays an essential role in 
the management of lymphomas, allowing for an evalu-
ation of the full extent of disease at baseline, accurate 
staging, adaptation of treatment strategies, assessment 
of treatment response and detection of relapses [7–10]. 
Positron emission tomography/computed tomography with 
[18F]-fluorodeoxyglucose (FDG-PET/CT) is commonly used 
for response assessment in lymphomas, but it is associated 
with radiation exposure, considerable cost, limited access, 
and FDG is also taken up at sites of infection and inflam-
mation, which is common in lymphoma patients [11–13]. 
Whole-body diffusion-weighted MR imaging was used to 
assess lymphomas, but the examination is time-consuming, 
expensive and may miss small lesions [14–19]. Whole-body 
PET-MR imaging has been recently applied for assessments 
in oncology, but it is not routinely available and still under 
trial [20]. Whole-body computed tomography (WBCT) was 
used in oncology and trauma patients [21–22]. Few studies 
discuss the role of routine contrast-enhanced CT for staging 
and follow-up of patients with lymphomas [23–25].
Aim of the work
To assess inter-observer agreement of WBCT in staging and 
treatment response assessment in lymphomas according to 
the Lugano classification.
Material and Methods
Institutional review board approval was obtained and 
informed consent from the patients was waived because 
this was a retrospective study. A retrospective study was 
conducted in 121 patients with lymphomas who under-
went WBCT. We included adult patients, aged 18 years 
or older, who were clinically scheduled to undergo CT for 
staging of newly diagnosed (histologically proven) Hodgkin 
or non-Hodgkin lymphomas. We excluded 6 patients from 
the study, because these patients had undergone CT with-
out contrast medium due to renal impairment. Finally, we 
included 115 patients (70 males and 45 females, aged 18 to 
88 years). The patients presented with fever, pain, weight 
loss, easy fatigability, swellings, constipation, abdomi-
nal enlargement, dysphagia, hoarseness of voice, cough, 
vomiting, pallor and night sweating. Lymphoma sub-
types were diagnosed based on tissue samples obtained by 
biopsy or surgery, according to the criteria of the current 
WHO classification of hematological and lymphoid malig-
nancies [26]. Patients with Hodgkin lymphomas received 
chemotherapy (ABVD – adriamycine, bleomycine, vinblas-
tine, decarbazine) and patients with non-Hodgkin lym-
phomas received CHOP (cyclophosphamide, adriamycine, 
oncovin and prednisone). Follow-up WBCT examinations 
were performed in 103 patients after a complete course of 
chemotherapy.
All patients were examined with a 64-MDCT scanner 
(Brilliance 64, Philips Medical Systems Cleveland, OH, 
USA). All patients were instructed to drink 1–1.5 L of 
water as oral contrast 30–60 minutes prior to examination. 
Intravenous injection of non-ionic contrast media (Ultravist 
300 mg/ml) at a dose of 1.5 ml/kg, via a power injector 
(Envision CT injector, MEDRAD, Pittsburgh, PA, USA), 
with a 20-G intravenous cannula placed in the antecubital 
fossa was performed at a rate of 3–5 ml/sec. CT examina-
tions were performed in the supine position with feet first. 
Scanning started 30–60 seconds after contrast injection, 
extended from the roof of the skull down to the symphysis 
pubis. A collimation of 64×0.6 mm with 0.5 second rota-
tion time and a pitch factor of 1.4 were chosen. The tube 
voltage was 120 kV, 100–200 mAs. All images were recon-
structed with an overlapping technique in the axial plane 
with an effective slice thickness of 1–1.5 mm and a recon-
struction increment of 0.7–0.8 mm. Multi-planar images in 
the sagittal and coronal planes with section thickness of 
4 mm were reconstructed. Baseline WBCT was performed 
2–12 days (mean of 5 days) before initiation of the first 
cycle of chemotherapy and response assessment was per-
formed 5–15 days (mean of 8 days) after completion of a 
full course of chemotherapy.
Image analysis was performed by 2 radiologists (AA, MA) 
with experience of 20 and 10 years in CT scan imaging, 
respectively. They were blinded to clinical findings and 
pathological diagnosis. They independently reviewed the 
images according to the Lugano classification for stag-
ing and response assessment in lymphomas [6]. The image 
analysis was performed for nodal and extra-nodal involve-
ment in different regions of the body using PACS (picture 
archiving and communication system) for all patients. 
Staging was done based on the extent of involvement of 
nodal groups, as follows: stage I, single lymph node group; 
stage II, multiple lymph node groups ipsilateral to the dia-
phragm; stage III, involvement of lymph node groups both 
above and below the diaphragm; and stage IV, noncontigu-
ous extra nodal involvement (e.g., liver, lung, or bone mar-
row) [6]. The Lugano criteria for response assessment using 
CT were: (a) complete radiologic response, all nodes smaller 
than or equal to 1.5 cm in the longest diameter, disappear-
ance of all CT findings of lymphoma; (b) partial remission, 
50% or greater decrease in disease burden; (c) stable dis-
ease, less than 50% decrease in disease burden; and (d) 
progressive disease, new or increased adenopathy or new 
extra-nodal lymphoma [6].
The statistical analysis of data was done by with the 
Statistical Package for Social Science,version 20 (SPSS 
Inc., Chicago, Ill, USA). The inter-observer agreement was 
expressed as a kappa (k) statistic with 95% confidence 
intervals (CI) and P value <0.05 was considered to indicate 
statistical significance. The k coefficient is the amount of 
observed agreement. A k of 0.0 represents agreement that 
is equal to chance, a k of 1.0 represents perfect agreement, 
a k of 0.81 to 1.0 is excellent agreement, 0.61 to 0.80 is 
good agreement, 0.41 to 0.60 is moderate agreement, 0.21 
to 0.40 is fair agreement and 0.0 to 0.20 represents slight 
agreement.
Results
The final pathological types of lymphomas were: non-
Hodgkin lymphomas in 102 patients (88.7%) and Hodgkin 
lymphomas in 13 patients (11.3%). The subtypes of the 
non-Hodgkin lymphomas were DLBCL in 69 patients (60%), 
Burkitt lymphoma in 8 patients (7%), follicular lymphoma 
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in 7 patients (6.1%), small cell lymphoma in 5 patients 
(4.3%), T-cell lymphoblastic lymphoma in 4 patients (3.5%), 
anaplastic lymphoma in 4 patients (3.5%), peripheral T-cell 
lymphoma in 2 patients (1.8%), mantle cell lymphoma in 
2 patients (1.8%) and MALT lymphoma in only one patient 
(0.9%). The subtypes of Hodgkin lymphomas were mixed 
cellularity type in 6 patients (5.2%), nodular sclerosis type 
in 5 patients (4.3%) and nodular lymphocytic predominance 
in 2 patients (1.7%).
Table 1 shows inter-observer agreement with respect to 
staging of lymphomas. Figure 1 shows the different stag-
es of lymphomas according to the Lugano classification. 
Stage I lymphoma was reported in 14 patients (12.1%) by 
observer 1 and in 13 patients (11.3%) by observer 2, with 
an excellent agreement (k=0.93 and percent of agree-
ment was 96.4%). Stage II lymphoma was reported in 18 
patients (15.8%) by observer 1 and in 20 patients (17.4%) 
by observer 2, with an excellent agreement (k=0.90 and 
the percent of agreement was 94.8%). Stage III lymphoma 
was reported in 33 patients (28.7%) by observer 1 and in 38 
patients (33.0%) by observer 2, with an excellent agreement 
(k=0.89 and the percent of agreement was 94.6%). Stage IV 
was reported in 50 patients (43.5%) by observer 1 and in 44 
patients (38.3%) by observer 2 with an excellent agreement 
(k=0.88 and the percent of agreement was 94%). The over-
all inter-observer agreement of WBCT in staging of lym-
phoma was excellent (k=0.90, percent agreement=94.9%).
Table 2 shows the final treatment response assessment of 
lymphomas. Complete response (Figure 2) was reported in 
13 patients (11.3%) by observer 1 and in 15 patients (13.1%) 
by observer 2, with an excellent agreement (k=0.87 and 
the percent of agreement was 93.3%). Partial response 
(Figure 3) was detected in 27 patients (23.5%) by observer 
1 and in 26 patients (22.6%) by observer 2, with an excel-
lent agreement (k=0.96 and the percent of agreement 
was 98.1%). Stable disease (Figure 4) was reported in 30 
patients (26.1%) by observer 1 and in 27 patients (23.5%) 
by observer 2, with an excellent agreement (k=0.90 and 
percent of agreement was 95%). Progressive disease 
(Figure 5) was reported in 33 patients (28.7%) by observer 
1 and in 35 patients (30.4%) by observer 2, with an excel-
lent agreement (k=0.94 and the percent of agreement was 
97.1%). Both observer 1 and observer 2 lost 12 patients 
(10.4%) to follow-up. The overall inter-observer agreement 
in response assessment was excellent (k=0.91, percent 
agreement=95.8%).
Discussion
In the present study, WBCT could detect nodal and extra-
nodal spread of the disease in different regions of the 
body within a short examination time. There is an excel-
lent inter-observer agreement of WBCT in staging of lym-
phoma (k=0.90, percent agreement=94.9%) and treatment 
response assessment (k=0.91, percent agreement=95.8%).
Pre- and posttreatment imaging for staging and treatment 
response assessment in lymphoma patients varies widely 
by center. The Lugano classification represents a consen-
sus statement of clinical experts in lymphoma and is there-
fore expected to serve as a unified guideline for all physi-
cians involved in lymphoma staging and response assess-
ment. Contrast-enhanced CT will allow for more accurate 
measurements of node size if required for clinical trials and 
will help better discern adenopathy from the surrounding 
soft-tissue structures. The new response criteria should 
Stage Observer 1 Observer 2 K Percent agreement
Stage I 14 (12.1%) 13 (11.3%) 0.93 96.4%
Stage II 18 (15.7%) 20 (17.4%) 0.90 94.8%
Stage III 33 (28.7%) 38 (33.0%) 0.89 94.6%
Stage IV 50 (43.5%) 44 (38.3%) 0.88 94.0%
Overall 0.90 94.9%
Table 1. Inter-observer agreement of staging of lymphoma.
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facilitate a simple assessment of treatment response 
in order to guide clinical management. Owing to these 
criteria, radiologists have a renewed opportunity to guide 
clinical management based on imaging findings [4–6].
In this study, there was an excellent inter-observer agree-
ment of WBCT in staging of nodal and extra-nodal of lym-
phoma. One study reported that staging of lymphomas is 
a vital pre-requisite to appropriate therapeutic manage-
ment and prognostication [3]. Another study added that 
whole-body diffusion-weighted MR imaging and FDG 
C D
E Figure 1.  Stages of lymphomas: (A) Axial, contrast CT scan of the abdomen shows a single splenic focal lesion 
(stage I). (B) Axial, contrast CT scan of the chest shows 
an amalgamated mass of multiple enlarged lymph nodes 
ipsilateral to the diaphragm (stage II). (C) Coronal WBCT 
shows enlarged axillary lymph nodes above the diaphragm 
and splenic focal lesions below the diaphragm (stage III). 
(D, E) Coronal WBCT shows multifocal hepatic lesions with 
multiple pulmonary nodules (stage IV).
Original Article
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PET/CT showed an overall good agreement (K=0.796, 95% 
IC=0.651–0.941), especially in the evaluation of the nodal 
basins in NHL (K=0.937, 95% IC=0.814–1) [27].
In this study, there was an excellent agreement between 
both reviewers with regard to treatment response assess-
ment. In practice, posttreatment imaging in lymphoma 
patients varies widely by center and will probably remain 
variable despite the new consensus guidelines. Residual 
masses are seen on anatomic imaging in up to 80% of 
patients with HL and 40% of those with NHL [3]. One study 
reported that, in reference to the revised response criteria 
for malignant lymphomas, whole-body MR imaging and 
whole-body diffusion MR imaging showed a good agree-
ment (K=0.824, 95% IC=0.493–1) [27]. Another study added 
that, with regard to treatment response assessment, diffu-
sion-weighted MR imaging agreed with 18F-FDG-PET/CT 
in 99/102 of follow-up examinations (97.1%), with a kappa 
value of 0.94 (P<.0001) [28].
Stage Observer 1 Observer 2 K Percent agreement
Progressive disease 33 (28.7%) 35 (30.4%) 0.94 97.1%
Stable disease 30 (26.1%) 27 (23.5%) 0.90 95.0%
Partial response 27 (23.5%) 26 (22.6%) 0.96 98.1%
Complete response 13 (11.3%) 15 (13.1%) 0.87 93.3%
Lost follow up 12 (10.4%) 12 (10.4%)
Overall 0.91 95.8%
Table 2. Inter-observer agreement of response assessment of lymphoma.
A B
Figure 2.  Complete response: (A) Axial, contrast CT before therapy shows enlarged mediastinal lymph nodes. (B) Axial, contrast CT scan after 4 
cycles of chemotherapy shows complete disappearance of the target nodes.
A B
Figure 3.  Partial response: (A) Axial CT shows enlarged inguinal lymph nodes. (B) Axial, contrast CT shows a regressive course with decreased sizes 
of inguinal lymph nodes.
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CT is the most commonly used imaging modality for stag-
ing and response assessment in lymphoma because of its 
widespread availability, relatively low cost, rapid exami-
nation, very short scanning time and excellent resolution. 
The drawbacks of CT include patient exposure to ionizing 
radiation and administration of iodinated contrast medium 
[29,30]. An important disadvantage of CT is the use of ion-
izing radiation which may be associated with induction of 
secondary cancers in later life, administration of iodinated 
contrast agents that may cause adverse reactions, including 
contrast-induced nephrotoxicity. CT lacks functional infor-
mation, which impedes identification of disease in normal-
sized nodes [14,15].
There are a few limitations of this study. First, this study 
was done using only WBCT and further studies with 
application of dual-energy CT [31–33], WB-PET-CT and 
A B
Figure 4.  Stable Disease: (A) Axial, contrast CT scan shows focal lesions in the left thyroid lobe. (B) Axial, contrast CT scan after a complete course of 
chemotherapy shows stable appearance of the left thyroid focal lesion.
A B
Figure 5.  Progressive disease: (A) Axial CT scan shows few small focal lesions in the spleen. (B) Axial CT scan after a complete course of 
chemotherapy shows increased sizes and number of the splenic focal lesions.
whole-body diffusion MR imaging will improve the results. 
Second, this study was done in patients with lymphomas. 
Further studies in subtypes of non-Hodgkin lymphomas are 
recommended. Third, image analysis for response assess-
ment was performed for one study after therapy; further 
studies with interim analyses after 2–3 cycles of chemo-
therapy are needed. Moreover, analysis of long-term sur-
veillance of the tumor will enhance the role of imaging in 
these patients.
Conclusions
We concluded that WBCT is a reliable and reproduc-
ible imaging modality for staging and treatment response 
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